Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

 Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Shots:

  • The P-III study involves assessing JZP-258 vs PBO in 201 patients with narcolepsy + cataplexy prior treated with Xyrem, naive to Xyrem, or with/without anti-cataplectic treatments
  • The P-III study results: met its 1EPs & 2EPs; reduction in no. of cataplexy attacks in a week and Epworth Sleepiness Scale score
  • JZP-258 is an oxybate therapy targeting GABAB receptor with a unique composition of cations resulting in 92% less sodium than Xyrem (sodium oxybate) and is evaluated for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy & idiopathic hypersomnia. Jazz also plans to file NDA for JZP-258 based on above results

Click here to read full press release/ article | Ref: Jazz Pharmaceuticals | Image: Studios Architecture

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post